m6A-centered Crosstalk Information

Mechanism of Crosstalk between m6A Modification and Epigenetic Regulation
Crosstalk ID
M6ACROT00192
 [1], [2], [3]
m6A modification ADAR1 ADAR1 METTL3 Methylation : m6A sites Direct Enhancement RNA modification Stat1 Stat1 ADAR Methylation : modification sites
m6A Modification:
m6A Regulator Methyltransferase-like 3 (METTL3) WRITER
 Regulator Info 
m6A Target Interferon-inducible protein 4 (ADAR1)
 Targert Gene 
Epigenetic Regulation that have Cross-talk with This m6A Modification:
Epigenetic Regulation Type RNA modification (RNAMod)  >> Adenosine-to-Inosine editing (A-to-I)
Epigenetic Regulator Interferon-inducible protein 4 (ADAR1) WRITER View Details
Regulated Target Transcription factor ISGF-3 components p91/p84 (Stat1) View Details
Crosstalk Relationship m6A  →  A-to-I Enhancement
Crosstalk Mechanism m6A modification directly impacts RNA modification through modulating the expression level of RNA modification regulator
Crosstalk Summary METTL3 methylates Interferon-inducible protein 4 (ADAR1) mRNA, thereby enhancing its protein expression, which subsequently promotes ADAR mediated A-to-I RNA editing of the Transcription factor ISGF-3 components p91/p84 (STAT1) transcript.
Responsed Drug Peptide analog 8
 Drug Info 
Pathway Response mRNA surveillance pathway hsa03015
RNA degradation hsa03018
Cell Process RNA stability
In-vitro Model
 MGG8 Glioblastoma Homo sapiens CVCL_D1H4
U-87MG ATCC Glioblastoma Homo sapiens CVCL_0022
U-118MG Astrocytoma Homo sapiens CVCL_0633
AGS Gastric adenocarcinoma Homo sapiens CVCL_0139
Full List of Potential Compound(s) Related to This m6A-centered Crosstalk
Transcription factor ISGF-3 components p91/p84 (Stat1) 6 Compound(s) Regulating the Target Click to Show/Hide the Full List
 Compound Name Peptide analog 8 Patented [4]
Synonyms
PMID26394986-Compound-2
    Click to Show/Hide
MOA Inhibitor
External Link
TTD: D0JF5K
 Compound Name Oxazole derivative 1 Patented [4]
Synonyms
PMID26394986-Compound-8
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 159000 nM
External Link
CID: 24768190
TTD: D0EZ6V
 Compound Name Peptidomimetic analog 5 Patented [4]
Synonyms
PMID26394986-Compound-7
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 42000 nM
External Link
CID: 9870708
TTD: D0XQ3F
 Compound Name Platinum IV complexe 1 Patented [4]
Synonyms
PMID26394986-Compound-69
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 4100 nM
External Link
TTD: D01BVU
 Compound Name PMID26394986-Compound-10 Patented [4]
MOA Inhibitor
Activity IC50 > 160000 nM
External Link
CID: 252682
TTD: D0TU0X
 Compound Name AVT-02 UE Discontinued in Phase 2 [5]
MOA Inhibitor
External Link
TTD: D03WRN
References
Ref 1 N?-Methyladenosine Landscape of Glioma Stem-Like Cells: METTL3 Is Essential for the Expression of Actively Transcribed Genes and Sustenance of the Oncogenic Signaling. Genes (Basel). 2019 Feb 13;10(2):141. doi: 10.3390/genes10020141.
Ref 2 ADAR1 is a new target of METTL3 and plays a pro-oncogenic role in glioblastoma by an editing-independent mechanism. Genome Biol. 2021 Jan 28;22(1):51. doi: 10.1186/s13059-021-02271-9.
Ref 3 ADAR1 Suppresses Interferon Signaling in Gastric Cancer Cells by MicroRNA-302a-Mediated IRF9/STAT1 Regulation. Int J Mol Sci. 2020 Aug 27;21(17):6195. doi: 10.3390/ijms21176195.
Ref 4 A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421.
Ref 5 Avontec Announces Results of a Multiple Dose Clinical Phase I Study with Its Drug Candidate AVT-02 UE Ointment After Topical Treatment in Male Healthy Volunteers. Avontec. 2008.